Long-term atorvastatin-ezetimibe-probucol triple therapy for homozygous familial hypercholesterolaemia from early childhood.
Cardiol Young
; 26(1): 197-201, 2016 Jan.
Article
em En
| MEDLINE
| ID: mdl-25907359
ABSTRACT
In this observational case report, we share our experience of achieving >40% LDL cholesterol reduction in four Chinese homozygous familial hypercholesterolaemia children below 8 years of age with a triple combination of atorvastatin, probucol, and ezetimibe for >6 years. Within a follow-up duration of 6-13 years, this triple therapy achieved significant reduction of LDL cholesterol as well as an impressive regression of xanthomas in all paediatric cases. All the children remained free from treatment-related adverse responses and cardiovascular events throughout follow-up.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Probucol
/
Ezetimiba
/
Atorvastatina
/
Hiperlipoproteinemia Tipo II
/
Anticolesterolemiantes
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article